MicroRNA‑134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1

Li,Jipeng; Chen,Ying; Jin,Mingwei; Wang,Jianhua; Li,Shanfeng; Chen,Zhe; Yu,Wanjun

doi:10.3892/ol.2017.5574

MicroRNA‑134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1

Authors:
- Jipeng Li
- Ying Chen
- Mingwei Jin
- Jianhua Wang
- Shanfeng Li
- Zhe Chen
- Wanjun Yu
View Affiliations

Affiliations: Department of Central Laboratory, Yinzhou People's Hospital, Ningbo, Zhejiang 315040, P.R. China, Department of Respiratory and Critical Care Medicine, Yinzhou People's Hospital, Ningbo, Zhejiang 315040, P.R. China
Published online on: January 5, 2017 https://doi.org/10.3892/ol.2017.5574
Pages: 1451-1455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) is the primary barrier to the success of chemotherapy for lung adenocarcinoma. MicroRNA (miR)‑134, which is downregulated in lung adenocarcinoma, influences cell proliferation, apoptosis and invasion of lung adenocarcinoma. However, the function of miR‑134 in the MDR of lung adenocarcinoma remains unclear. In the present study, it was identified that miR‑134 expression is significantly downregulated in A549/cisplatin MDR lung adenocarcinoma cells, as compared with A549 parental cells. miR‑134 regulates the sensitivity of lung adenocarcinoma cells to certain anticancer drugs. Furthermore, it was demonstrated that forkhead box M1 and multidrug resistance‑associated protein 1 are functional targets of miR‑134. These data revealed an important role for miR‑134 in the regulation of MDR in lung adenocarcinoma.

View Figures

View References

1	Szákacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
2	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
3	Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F and Wang X: Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine. 8:1867–1877. 2013.PubMed/NCBI
4	Kuss S, Polcari D, Geissler M, Brassard D and Mauzeroll J: Assessment of multidrug resistance on cell coculture patterns using scanning electrochemical microscopy. Proc Natl Acad Sci USA. 110:9249–9254. 2013. View Article : Google Scholar : PubMed/NCBI
5	Xu K, Liang X, Cui D, Wu Y, Shi W and Liu J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 52:70–78. 2013. View Article : Google Scholar : PubMed/NCBI
6	Baer C, Claus R and Plass C: Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xu K, Liang X, Shen K, Cui D, Zheng Y, Xu J, Fan Z, Qiu Y, Li Q, Ni L and Liu J: miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J. 446:291–300. 2012. View Article : Google Scholar : PubMed/NCBI
8	An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P, Nie Y and Zhao Q: miR-23b-23p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 6:e17662015. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Yang J, Xu G, Wang W, Liu C, Yang H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget. 6:3147–3164. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ottman R, Nguyen C, Lorch R and Chakrabarti R: MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer. 13:12014. View Article : Google Scholar : PubMed/NCBI
11	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Li J, Wang Y, Song Y, Fu Z and Yu W: miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 13:1932014. View Article : Google Scholar : PubMed/NCBI
14	Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y and Yu W: miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 n non-small cell lung cancer cells. FEBS Lett. 586:3721–3725. 2012. View Article : Google Scholar
15	Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 7:1798–1804. 2001.PubMed/NCBI
16	Doubre H, Césari D, Mairovitz A, Bénac C, Chantot-Bastaraud S, Dagnon K, Antoine M, Danel C, Bernaudin JF and Fleury-Feith J: Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer. 113:568–574. 2005. View Article : Google Scholar : PubMed/NCBI
17	Li J, Li ZN, Du YJ, Li XQ, Bao QL and Chen P: Expression of MRP1, BCRP, LRP and ERCC1 in advanced non-small-cell lung cancer: Correlation with response to chemotherapy and survival. Clin Lung Cancer. 10:414–421. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sun CC, Li SJ and Li DJ: Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget. 7:35960–35978. 2016.PubMed/NCBI
19	Gao Y, Liu T and Huang Y: MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Lett. 589:207–214. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, et al: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B and glioblastoma. Cell Death Diff. 21:720–734. 2014. View Article : Google Scholar
21	Wang Z, Ahmad A, Li Y, Banerjee S, Kong D and Sarkar FH: Forkhead box M1 transcription factor: A novel target for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
22	Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R and Huang S: Aberrant FOXM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene. 26:6212–6219. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF and Chou CY: FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 6:2349–2365. 2015. View Article : Google Scholar : PubMed/NCBI
24	Tan Y, Raychaudhuri P and Costa RH: Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 27:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 8:24–34. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hodge G, Holmes M, Jersmann H, Jersmann H, Reynolds PN and Hodge S: The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. Respir Res. 14:632013. View Article : Google Scholar : PubMed/NCBI
27	Lu JF, Pokharel D and Bebawy M: MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 47:406–419. 2015. View Article : Google Scholar : PubMed/NCBI